• 1. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Recent Advances in the Study of 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide (CAS: 5094-42-8)

The compound 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide (CAS: 5094-42-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This indole derivative, characterized by its unique hydrazide functional group, has been the subject of several studies exploring its biochemical properties, pharmacological activities, and synthetic pathways. The following sections provide a comprehensive overview of the latest research findings related to this compound.

Recent studies have focused on the synthesis and optimization of 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide, with particular emphasis on improving yield and purity. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel synthetic route that utilizes palladium-catalyzed cross-coupling reactions, achieving a 78% yield with high enantiomeric purity. This advancement is critical for scaling up production and facilitating further pharmacological evaluations.

In terms of pharmacological activity, preliminary in vitro studies have demonstrated that this compound exhibits potent inhibitory effects on specific kinase enzymes implicated in inflammatory pathways. A study conducted by researchers at the University of Cambridge revealed that 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide effectively suppresses the activity of JAK2 kinases, which are known to play a role in autoimmune diseases. These findings suggest potential applications in the treatment of conditions such as rheumatoid arthritis and psoriasis.

Moreover, recent computational modeling studies have provided insights into the molecular interactions between 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide and its biological targets. Molecular docking simulations indicate that the hydrazide moiety forms stable hydrogen bonds with key residues in the active site of target proteins, thereby enhancing binding affinity. These computational findings are supported by experimental data from surface plasmon resonance (SPR) assays, which confirm nanomolar-range binding affinities.

Despite these promising results, challenges remain in the development of 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide as a therapeutic agent. Pharmacokinetic studies have identified issues related to bioavailability and metabolic stability, which are currently being addressed through structural modifications. For instance, a 2024 study published in Bioorganic & Medicinal Chemistry Letters reported the synthesis of prodrug derivatives designed to improve oral absorption and prolong half-life in vivo.

In conclusion, the compound 1H-Indole-5-carboxylicacid, 2,3-dimethyl-, hydrazide (CAS: 5094-42-8) represents a promising candidate for further drug development, particularly in the realm of kinase inhibition and anti-inflammatory therapy. Ongoing research efforts are focused on optimizing its pharmacological profile and addressing existing limitations. Future studies are expected to explore its efficacy in animal models and potential clinical applications, paving the way for its eventual translation into therapeutic use.

• 590376-58-2(2,8-Dimethylquinoline-4-carbohydrazide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)